Evidence map›Paper›PMID 35008241›Full record

ArticleCancers2021

Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease.

Chaobo Chen, Hanghang Wu, Hui Ye, Agustín Tortajada, Sandra Rodríguez-Perales, Raúl Torres-Ruiz, August Vidal, Maria Isabel Peligros, Johanna Reissing, Tony Bruns and 19 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 5 countries.

Chaobo ChenDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.ORCID 0000-0001-5963-5295
Hanghang WuDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
Hui YeDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
Agustín TortajadaDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
Sandra Rodríguez-PeralesMolecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.
Raúl Torres-RuizMolecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.
August VidalLaboratorio de Investigación Traslacional (LRT1)-ProCURE, Institut Català d'Oncologia (ICO)-IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0001-5727-2099
Maria Isabel PeligrosInstitute of Pathology, Hospital Universitario Gregorio Marañon, 28007 Madrid, Spain.
Johanna ReissingDepartment of Internal Medicine III, University Hospital RWTH, 52074 Aachen, Germany.
Tony BrunsDepartment of Internal Medicine III, University Hospital RWTH, 52074 Aachen, Germany.ORCID 0000-0002-5576-6914
Mohamed Ramadan MohamedDepartment of Internal Medicine III, University Hospital RWTH, 52074 Aachen, Germany.
Kang ZhengDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.ORCID 0000-0001-6778-2607
Amaia LujambioLiver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-2798-1481
Maria J IraburuDepartment of Biochemistry and Genetics, University of Navarra, 31008 Pamplona, Spain.
Leticia ColynHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-7403-9149
Maria Ujue LatasaHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.
María ArechederraHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-4830-1924
Maite G Fernández-BarrenaHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-0375-6236
Carmen BerasainHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-7075-2476
Javier VaqueroCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-8903-7288
Rafael BañaresCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Leonard J NelsonInstitute for Bioengineering (IBioE), Faraday Building, The University of Edinburgh, Edinburgh EH8 9AB, UK.ORCID 0000-0002-4197-4843
Christian TrautweinDepartment of Internal Medicine III, University Hospital RWTH, 52074 Aachen, Germany.
Roger J DavisHoward Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01655, USA.ORCID 0000-0002-0130-1652
Eduardo Martinez-NavesDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
Yulia A NevzorovaDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
Alberto VillanuevaLaboratorio de Investigación Traslacional (LRT1)-ProCURE, Institut Català d'Oncologia (ICO)-IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0001-5164-0006
Matias A AvilaHepatology Program, Cima, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6570-3557
Francisco Javier CuberoDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.ORCID 0000-0003-1499-650X
Universidad Complutense de Madrid · ESInstituto de Salud Carlos III · ESRWTH Aachen University · DEUniversidad de Navarra · ESInstitut d'Investigació Biomédica de Bellvitge · ESSpanish National Cancer Research Centre · ESHospital General Universitario Gregorio Marañón · ESHoward Hughes Medical Institute · USIcahn School of Medicine at Mount Sinai · USUniversity of Edinburgh · GB

Funding

BBSRC Grant BB/L023687/1EPSRC IAA Grant PIII013Scientific Research Project of Wuxi Municipal Health Commission M202160Several This research was funded by the MINECO Retos PID2020-117941RB-IOO, SAF2016-78711 and SAF2017-87919-R, MINECO Retos PID2019-104878RB-100AEI/10.13039/501100011033, EXOHEP-CM S2017/BMD-3727, NanoLiver-CM Y2018/NMT-4949, ERAB Ref. EA 18/14, AMMF 2018/117, UCM
6 · The paper itself

Abstract

Fibropolycystic liver disease is characterized by hyperproliferation of the biliary epithelium and the formation of multiple dilated cysts, a process associated with unfolded protein response (UPR). In the present study, we aimed to understand the mechanisms of cyst formation and UPR activation in hepatocytic c-Jun N-terminal kinase 1/2 (

Indexed as

cholangiocarcinoma (CCA)c-Jun N-terminal kinases (JNK)CM272endoplasmic reticulum (ER) stressfibropolycystic liver diseasethioacetamide (TAA)

Identifiers

PMID35008241
PMCPMC8750579
OpenAlexW4200581508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.